Positive allosteric modulators of GABA A receptors transduce a host of beneficial effects including anxiolytic actions. We have recently shown that bioavailability and anxiolytic-like activity can be improved by eliminating the ester functionality in imidazo [1,5-a] [1,4]diazepines. In the present series of experiments, we further substantiate the value of heterocyle replacement of the ester for potential treatment of anxiety. None of three esters was active in a Vogel conflict test in rats that detects anxiolytic drugs like diazepam. Compounds 7 and 8, ester bioisosters, were selective for alpha 2 and 3 over alpha 1-containing GABA A receptors but also had modest efficacy at GABAA alpha 5-containing receptors. Compound 7 was efficacious and potent in this anxiolyticdetecting assay without affecting non-punished responding. The efficacies of the esters and of compound 7 were predicted from their efficacies as anticonvulsants against the GABA A antagonist pentylenetetrazole (PTZ). In contrast, the related structural analog, compound 8, did not produce anxiolytic-like effects in rats despite anticonvulsant efficacy. These data thus support the following conclusions: 1) ancillary pharmacological actions of compound 8 might be responsible for its lack of anxiolytic-like efficacy despite its efficacy as an anticonvulsant 2) esters of imidazo[1,5-a][1,4]diazepines do not demonstrate anxiolytic-like effects in rats due to their low bioavailability and 3) replacement of the ester function with suitable heterocycles markedly improves bioavailability and engenders molecules with the opportunity to have potent and efficacious effects in vivo that correspond to human anxiolytic actions.
Introdution
The efficacy and value of 1,4-benzodiazepines as anxiolytic agents started prior to their identification as positive allosteric modulators of GABA (Haefely et al., 1975; Tallman et al., 1980) . Their continued use as anxiolytics has been sustained for nearly 60 years. These agents are acutely active unlike the SSRI anti-anxiety drugs (Katz et al., 2004) . Despite their relative safety (Woods et al., 1987; Schroeck et al., 2016) and over-the-counter sales in many countries, benzodiazepine anxiolytics have come under scrutiny in the last few decades due to reports of abuse and dependence and concerns of drug interactions (e.g., ethanol) (Kaplan and DuPont, 2005) . Further, the motoric effects of ataxia and myorelaxation have raised concerns with potential impact on daily function (e.g., driving cars) (Strand et al., 2016) .
Since the initial discovery of the potential for multiple subtypes of benzodiazepine receptors in 1979, a search for anxiolytics with reduced sedative and dependence liability has been ongoing (Lippa et al., 2005; Skolnick, 2012) . The cloning and expression of GABA A receptors identified multiple subtypes based upon subunit composition (Sieghart and Ernst, 2005) . A particular focus has been on the α subunits comprising the ion channel since these subunits have remarkable impact on pharmacological activity with important implication for therapeutics. Alpha 1-associated GABA A receptors have long-been associated with sedative effects (McKernan et al., 2000) and this understanding led to the successful discovery and development of multiple α1-selective drugs as sleep enhancers (Langer et al., 1992) . Since α2/3-containing GABA A receptors have been associated with anxiolytic effects with reduced sedative liability (Rivas et al., 2009; Fischer et al., 2010; Atack, 2011; Ralvenius et al., 2015) , this mechanism remains a viable avenue for novel drug discovery. In addition convergent data has suggested also the possibility that α2/3-containing GABA A receptor agonists would have reduced dependence and abuse liability (Kohut and Ator, 2008; Ator et al., 2010) . However, other data has pointed out that partial agonism at these sites might also be important for these benefits (Ator et al., 2010) and that α2 sites in the nucleus accumbens are essential for the reinforcing effects of benzodiazepines like midazolam (Engin et al., 2014) .
We recently reported on several analogs of the anxiolytic ester drug HZ-166 with improved bioavailability and efficacy (Poe et al., 2016) . In that study, HZ-166 (compound 2 in Poe et al., 2016 ) decreased marbleburying, an effect that occurs with acute dosing with anxiolytic standards including SSRIs (Li et al., 2006) . Compounds 7 and 8, both ester bioisosters, tended to have greater efficacy, and in the case of compound 7, to have greater potency (Poe et al., 2016) . Importantly, in a conflict test in rats that detects anxiolytic drugs, HZ-166 was not active whereas another ester bioisosters of HZ-166, KRM-II-81 (compound 9 described in Poe et al., 2016) was efficacious. Compound 9 also attenuated acid-induced pain behaviors in mice (Lewter et al., 2017) . The present series of studies was conducted to characterize three additional esters and two analogs with heterocyclic replacement of the ester as in . In order to deduce in vivo activity of these compounds, we conducted anticonvulsant studies against the GABA A receptor antagonist pentylenetetrazole. It was predicted that the ligands with in vivo activity as anticonvulsants, actions known to have a large α2 contribution (Fradley et al., 2007) , would also be anxiolytic as had been suggested by another series of non-selective GABA A receptor ligands (Lippa et al., 1979) .
Methods

Potency and efficacy at GABA A receptors
Electrophysiology methods utilized the Ion Works Barracuda (IWB) system. Unless otherwise specified, all cell culture reagents were obtained from Thermo Fisher Scientific (Waltham, MA), and all other reagents were obtained from Sigma-Aldrich (St Louis, MO). Compound serial dilutions were prepared in dimethyl sulfoxide (DMSO) and diluted into external recording solution prior to the experiment. Final DMSO concentration was 0.3%.
For cell culture, HEK293 cells stably expressing hGABA A R (α1β3γ2), hGABA A R (α2β3γ2), hGABA A R (α3β3γ2) and hGABA A R (α5β3γ2) were obtained from ChanTest (Cleveland, OH). Cells were cultured at 37°C in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS, 1% non-essential amino acids, G418 (200 μg/ml), hygromycin (100 μg/ml), zeocin (50 μg/ml) and puromycin (0.1 μg/ml).
For IWB experiments, cells were cultured in T-150 flasks (Corning) to 80-90% confluency. Cells were rinsed twice with D-PBS without calcium and magnesium and dissociated by incubating in 3 ml of TrypLE™ (Thermo Fisher Scientific, Waltham, MA) for 5 min. Cells were then re-suspended in 10 ml of media, gently triturated, and centrifuged for 5 min at 1000 RPM. The supernatant was aspirated and the cells re-suspended in 5 ml HBSS-based external solution (see below).
During IWB recordings, cells were supplied and seals established in an external solution consisting of Hanks Balanced Salt Solution (HBSS) supplemented with 20 mM HEPES with pH adjusted to 7.4 using NaOH. The internal solution used was (in mM): 90 K-Gluconate; 40 KCl, 3.2 MgCl2; 3.2 EGTA and 5 HEPES; with pH adjusted to 7.2 using KOH. The membrane perforating agent amphotericin B was prepared as a 28 mg/ ml stock solution in DMSO on the day of the experiment and added to the internal solution at a concentration of 0.1 mg/ml.
Electrophysiological recordings were made as follows: The IWB instrument was primed with intracellular and extracellular solutions and 9 μl of cells (5 M/ml) added to each well. Recordings were performed in population patch clamp (PPC) mode, and the whole cell recording configuration was established by 8 min incubation with amphotericin B. The holding voltage was set to − 80 mV and sampling frequency was 1 kHz. Test compound was added during first compound addition. After three minute incubation with compound GABA currents were evoked with co-administration of GABA at approximately EC15 concentration together with test compound. For GABA CRC experiments increasing concentrations of GABA were applied during second compound addition.
Data acquisition, leak subtraction and initial analysis of peak currents during each test pulse were performed using IWB software (version 2.0.2; Molecular Devices Corporation, Union City, CA). Compounds were tested at 10 concentrations in four to six replicates. Mean and standard error of the normalized peak current amplitudes were fit to the Hill equation using GraphPad Prism 6.02 software (GraphPad Software, San Diego, CA). All error bars represent the Standard Error of the Mean (SEM).
Animal care and use
All studies were performed in accordance with guidelines of the National Institutes of Health and by local animal care and use committees.
Animals
Male, Sprague Dawley rats from Harlan Sprague Dawley (Indianapolis, IN) were used and weighed 90-110 g when evaluated in experiments. Rats were housed 5/cage with free access to water and food in a room with lights on at 6 am and off at 6 pm. Animals were maintained in the colony room for at least 3 days before testing. Animals were moved to a quiet room 1 h prior to the start of the test.
Inverted screen test
Prior to dosing rats with PTZ they were tested for potential motor impairment on an inverted screen. The apparatus is made of four 13 cm × 16 cm squares of round hole, perforated stainless steel mesh (18 holes/square inch, 3/16 in. diameter, 1/4 inch staggered centers, 50% open area) mounted 15 cm apart on a metal rod, 35 cm above the table top.
The rats were dosed with test compound and returned to their home cage. Twenty five minutes after pre-treatment, animals were tested on the inverted screen and were scored after 60 s as follows: (0 = climbed over, 1 = hanging on to screen, 2 = fell off). After the inverted screen test, animals were dosed with pentylenetetrazole (PTZ) in a volume of 1 ml/kg and placed in an observation cage (40.6 × 20.3 × 15.2 cm) with a floor containing 0.25 in. of wood chip bedding material. Mean ± S.E.M. scores were analyzed by ANOVA followed by posthoc Dunnett's test.
Pentylenetetrazole (PTZ)-induced seizures
Drugs were studied for their ability to prevent or dampen seizures induced in mice or rats after s.c. PTZ dosing. Animals were then observed for 30 min post PTZ for clonus (defined as clonic seizure of fore-and hindlimbs during which the mouse demonstrated loss of righting) or for tonic seizures as exemplified by loss of righting accompanied with tonic hindlimb extension. The dose of PTZ used in rat studies was 35 mg/kg, s.c., and the dose in mice was 70 mg/kg, i.p., based upon estimated ED 90 values for PTZ in these assays. The percentage of animals exhibiting convulsions was analyzed by Fisher's exact probability test.
Vogel conflict behavior
Day 1, animals are moved from colony room into test room and put into operant chambers with water available, white noise, and houselight on (program title Vogel train). A timer starts when the first lick is J.M. Witkin et al. Pharmacology, Biochemistry and Behavior 157 (2017) 35-40 made. For the first 3 min after the first lick, data is recorded as unpunished licks. After 3 min, the second component becomes active for 3 min. All licks in the second component are recorded as punished licks. At the end of the 6 min, the chamber goes dark. Animals are removed and returned to home cages. After all groups of animals have been exposed to the chambers, water is made available in the home cage for 30 min. After 30 min, water is removed and animals are transported back to colony room. Data for both components is recorded as the number of licks. Sometime data for day 1 and day 2 is not recorded due to operant chambers being used for other testing protocols. Data is always recorded for day 3. Day 2 conditions were identical to day one training. On day 3, animals were randomly assigned to dose groups and drugged according to route and pre-treatment times recorded below. Animals are run on program Vogel FR20, which is identical to Vogel training with the exception of during the 2nd component (punished), every 20th lick is shocked. Data for both components is recorded as the number of licks. Shock intensity = 0.5 mA, duration = 100 ms. Shock is delivered through the water sipper tube. Chlordiazepoxide (CDAP) 20 mg/kg, i.p., 30 min pre-session is used as a positive control. Injection volume is 1 ml/kg unless otherwise noted.
Compounds
Compounds were synthesized as described Poe et al., 2016) . Compound numbers are from Poe et al. (2016) . The other compounds were obtained from commercial suppliers: valproic acid, chlordiazepoxide HCl, and pentylenetetrazole (Sigma-Aldrich, St. Louis, MO, USA). Valproate, chlordiazepoxide and pentylenetetrazole were dissolved in water. The test compounds were suspended in 1% hydroxyethylcellulose/0.05% tween 80/0.05% Dow antifoam. Compounds were administered in a volume of 1 ml/kg except at higher concentrations where dose volumes up to 3 ml/kg were used. Test compounds were given 30 min prior to testing by the i.p. route.
Results
To evaluate the potentiation of the compounds towards different subtypes of GABA A receptor, GABA evoked currents were recorded on the Ion Works Barracuda (IWB) high-throughput electrophysiology platform. The negative current evoked by GABA application showed a rapid activation followed by a slow desensitization. The average maximum negative current amplitudes evoked with saturating concentration of GABA were similar for all subtypes; 0.9 nA for α1β3γ2 GABA A receptor, 0.8 nA for α2β3γ2 GABA A receptor, 1.0 nA for α3β3γ2 GABA A receptor and 0.9 nA for α5β3γ2 GABA A receptor, respectively. The potencies of GABA at individual subtypes are listed in Table 1 . For that purpose of this study the concentration of GABA was individually adjusted to EC 15 for each GABA A subtype. From day-to-day, we saw some variability in this value, and therefore the effective concentration was determined for each run as a percent of maximum GABA (1 mM) evoked current. Only experiments with efficacies ranging from EC 10 to EC 20 were used in the analysis.
Compounds 7 and 8 potentiated GABAA currents (Fig. 2 , Table 1 ). The potency was however substantially lower at the α 1 containing subtype than at α 2, α 3 or α 5 subtypes where the EC 50 s were approximately 10-fold lower (Table 1 ). In addition to lower compound potency at α1 containing GABA A receptors maximum potentiation of the GABA EC 15 -induced currents was less robust. The efficacy at α1 subtype was < 25% for all three compounds (Table 1) while the efficacy at α 2, α 3 or α 5 subtypes exceeded 60% for both compounds. The non-selective full agonist at benzodiazepine receptor, diazepam, produced similar potentiation (potency and efficacy) at all GABAA receptor subtypes tested (Fig. 2, Table 1 ).
The effects of test compounds (evaluated at 30 mg/kg, i.p.) on motor performances and anticonvulsant efficacy are shown in Table 2 . The esters (A, B, 3) were without significant motor impact or anticonvulsant effect. In contrast, compounds 7 and 8 were effective anticonvulsants without significant motor impairing effects.
The esters (A, B, 3) did not significantly increase punished responding nor affect non-punished responding (Fig. 3) . In contrast, compound 7 increased punished drinking without significantly altering non-punished drinking (Fig. 4) . Compound 8, on the other hand, decreased both punished and non-punished drinking (Fig. 5) . Given the lack of increase in punished responding with compound 8, we did an additional study with other doses. In that study, doses up to 17 mg/ kg were studied; no significant effect on either punished or nonpunished drinking was observed.
Discussion
Consistent with the low bioavailability of the esters of imidazo[1,5-a] [1,4] diazepines (Poe et al., 2016) , we found that all three esters studied were inactive in the Vogel conflict test in rats. Both oral and intraperitoneal dosing resulted in low drug exposures (Poe et al., 2016) which likely explain the lack of in vivo effects. In contrast, compound 7 was efficacious and potent in this anxiolytic-detecting assay without affecting non-punished responding. The efficacy of these molecules (A, Table 1 Data summary for test compounds 7 and 8 and a clinically approved benzodiazepine anxiolytic (diazepam). Electrophysiological measurements of HEK293 cells expressing human recombinant α1β3γ2, α2β3γ2, α3β3γ2, or α5β3γ2 GABA A R in the presence of compounds were measured by IW-Barracuda automated patch-clamp. Efficacy is expressed as % increase in the peak GABA EC 15 -evoked current. All values shown are mean ± SEM for a minimum of 4-6 replicates. Average EC 50 s of GABA (n = 2) are listed for each channel subtype.
Compound GABAA-a1 GABAA-a2 GABAA-a3 GABAA-a5 Fig. 1 . Structures of the compounds studied. Compounds 7, 8, and 9 correspond to compounds reported in Poe et al. (2016) . Compounds A, B, and 3 were originally reported in Cook et al. (2009 Cook et al. ( , 2010 and Fischer et al. (2010) .
J.M. Witkin et al. Pharmacology, Biochemistry and Behavior 157 (2017) 35-40 B, 3 and 7) was predicted from their efficacies as anticonvulsants against the GABA A receptor antagonist pentylenetetrazole (PTZ). The fact that the esters studied here were active in anxiolytic-detecting conflict tests in Rhesus monkeys (Fischer et al., 2010) but not in rats in the present study will require full comparative pharmacokinetic analysis to understand. Nonetheless, the higher hydrolysis of esters in rodents vs. primates (Schweri et al., 1983 ) is a likely reason for these differences. The mixed findings on the abilities of these esters to produce anxiolytic-like effects in rats in the elevated plus maze (Savić et al., 2008 (Savić et al., , 2010 had been suggested to be due to differences in ligand efficacies at GABA A α5 receptors. Given the qualitative differences in compounds A, B, and 3 to produce anxiolytic-like effects in the present J.M. Witkin et al. Pharmacology, Biochemistry and Behavior 157 (2017) 35-40 study along with the improved central exposure observed with compounds 7 and 9 (KRM-II-81) (Poe et al., 2016, compound 9) corresponding to their effects in the same assay, we suggest that central exposure by these molecules is a key determinant of their in vivo effects. This idea is given additional support by the anticonvulsant data provided in this report. In contrast, compound 8 did not significantly affect punished or non-punished responding in the Vogel assay. The lack of anxiolytic-like activity with compound 8 is surprising, given its ability to function as a modulator of the effects of pentylenetetrazole. We conclude that anticonvulsant efficacy against PTZ alone is not sufficient to predict anxiolytic efficacy at least for this very limited set of compounds. This conclusion is further supported by observations with HZ-166. In rats, 30 mg/kg, i.p., reduced convulsions induced by PTZ by 60%. In contrast, HZ-166 was not active in the Vogel conflict test (Poe et al., 2016) whereas the non-ester analog, KRM-II-81 (compound 9 in Poe et al., 2016) increased punished drinking in rats under the Vogel conflict test (Poe et al., 2016) .
We had previously demonstrated that the plasma and brain exposures of the ester bioisosters show remarkable improvement over their ester counterparts (Poe et al., 2016) . Although direct dose/ exposure comparisons are not available, data document that both the anxiolytic active (compound 7) and the anxiolytic inactive (compound 8) compounds exhibit high exposure in both brain and plasma of rats after i.p. dosing. At 150 mg/kg, i.p., compound 8 exposed brain to 33,400 ± 15,900 nM and plasma to 25,700 ± 10,400 nM (n = 3 rats). The very low efficacy of 8 at alpha α1-containing GABA A receptors is one notable difference in the pharmacological profile of compounds 7 and 8. However, given the association of α1 agonism with sedation (McKernan et al., 2000) , and the ability of other α2 and 3-selective modulators to produce anxiolytic-like effects in preclinical species (Rivas et al., 2009; Fischer et al., 2010; Atack, 2011; Ralvenius et al., 2015) and humans (Atack et al., 2006 (Atack et al., , 2011a , the lack of α1 efficacy of compound 8 is probably not relevant to its lack of anxiolytic activity reported here. Further studies on the differential pharmacologies of these compounds are required to properly place this negative effect in context of GABA A alpha 2/3 receptors.
To account for the differences in behavioral effects of 7 vs 8, we hypothesize that compound 8 has ancillary actions that competed with its effects at GABA A α2/3 receptors, the nature of which are not yet determined. Indeed, compound 8 showed more behavioral depressant activity than compound 7 and displayed a statistical trend to decreasing unpunished drinking (p = 0.08). Compound 8 also appeared to be more cytotoxic than compound 7 in human embryonic kidney cells (HEK293T) (Poe et al., 2016) .
A compelling clinical opportunity exists in the development of α1 sparing subtype-selective GABA A receptor ligands. These ligands are expected to result in superior treatments for seizures and anxiety without causing sedation, amnesia and ataxia, or the propensity for addiction and tolerance development. NS11394 (Mirza et al., 2008) which displayed agonistic activity for the α2, α3 and α5 subtypes was shown to be anxiolytic; however, it also decreased memory, likely due to the activation of the α5 subtype (Mirza et al., 2008) In fact, NS11394 had greater efficacy at GABA A α5 receptors than GABA A receptors constituted by other alpha subunits (Mirza et al., 2008) . In contrast, the ligands reported here (cpds 7 and 8) also had affinity and efficacy as agonists of GABA A α5 receptors though were generally less than that at the other alpha subtypes examined as also exemplified from GABA currents recorded from Xenopus oocytes (Lewter et al., 2017) . NS11821, another molecule that positively modulates α2, α3, and α5-comprised GABA A receptors, was less sedating and produced less body sway and subjectively-reported sedation than lorazepam in humans (Zuiker et al., 2016) . Additionally, continued research has seen a number of promising candidates fail due to pharmacokinetic complications or other adverse effects. One ligand, the α2/α3-positive allosteric modulator TPA023 (Atack et al., 2006) was shown to be a relatively non-sedating anxiolytic in humans (Atack, 2009 ) but ultimately led to cataracts (Mohler, 2011) . In contrast, other attempts to create reduced motor impacting anxiolytic drugs have not been as successful. For example, MRK-409 (MK-0343) was sedating in humans in contrast to preclinical predictions (Atack et al., 2011b) . These results indicate that a ligand which activates only the α2/α3-GABA A R subtypes may be useful for the treatment of anxiety but the proof of this has yet to be achieved in pill form (Skolnick, 2012) .
The data presented here support the following conclusions: 1) esters of imidazo[1,5-a][1,4]diazepines have low bioavailability, 2), replacement of the ester function with suitable heterocycles markedly improves bioavailability (Poe et al., 2016) and imbues molecules with potent and efficacious effects in vivo that can correspond to human anxiolytic actions. In conclusion, the present series of experiments has provided further substantiation of the viability of imidazo[1,5-a][1,4] diazepines as novel allosteric modulators of GABA A receptors which may have clinical utility as anxiolytics. Moreover, an additional promise of such sub-type selective drugs is in the treatment of pain (Ralvenius et al., 2015) . Given the co-morbidity of pain and anxiety (Bandelow, 2015) and the recent findings that molecules selective for α2/α3 or α2/α3/α5-containing GABA A receptors (de Lucas et al., 2015) including compound 9 (Lewter et al., 2017) were efficacious in rodent pain models as amply predicted for these alpha protein subunit targets (Ralvenius et al., 2015) , such potentiators of α2/α3-constituted GABA A receptors are predicted to be valuable additions to the therapeutic arsenal for patients in the future. Performed data analysis: JM Witkin, SD Gleason, R. Cern. Wrote or contributed to the writing of the manuscript: All authors. J.M. Witkin et al. Pharmacology, Biochemistry and Behavior 157 (2017) 35-40 Analytical Chemistry and support from the Milwaukee Institute of Drug Discovery and the University of Wisconsin-Milwaukee Research Foundation.
